Similar articles

Abstract: Objective: Although drug-eluting stent (DES) implantation is the primary treatment modality for bare-metal stent (BMS) in-stent restenosis (ISR), little is known about the efficacy and safety profile of DES in the treatment of DES-ISR. The goal of this study was to compare the clinical outcomes following DES treatment for BMS-ISR and DES-ISR. Methods: Rates of major adverse cardiac events (MACE) were compared in 97 consecutive patients who underwent DES implantation for the treatment of ISR (56 BMS-ISR and 41 DES-ISR) from January 2004 to December 2008. Results: Baseline clinical and procedural characteristics were comparable, except that the DES used in the BMS-ISR group was longer and had a larger diameter. The length of follow-up was (28.60±1.96) and (20.34±1.54) months for the BMS-ISR and DES-ISR groups, respectively. One patient (1.8%) experienced non-cardiac mortality and one (1.8%) had target-vessel revascularization (TVR) in the BMS-ISR group. In the DES-ISR group, three patients (7.3%) died of sudden death with a documented acute ST-segment elevation myocardial infarction, and three suffered TVR (7.3%). Kaplan-Meier analysis indicated that cumulative survival probability and MACE-free probability were both significantly lower for the DES-ISR group (log rank test P=0.047 and P=0.005, respectively). In Cox regression analysis, DES-ISR remained an independent predictor for future MACE occurrence after adjustment for other factors (compared with BMS-ISR, risk ratio (RR)=8.743, 95% confidence interval (CI) 1.54–49.54, P=0.014). Switching to a different type of DES to treat DES-ISR did not improve the prognosis. Conclusion: DES-ISR patients had a poorer prognosis than BMS-ISR patients after DES therapy.

[1]Alfonso, F., Pérez-Vizcayno, M.J., Hernandez, R., Bethencourt, A., Martí, V., López-Mínguez, J.R., Angel, J., Mantilla, R., Morís, C., Cequier, A., et al., 2006. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the restenosis intrastent balloon angioplasty versus elective sirolimus-eluting stenting (RIBS-II) trial. Journal of the American College of Cardiology, 47(11):2152-2160.

[2]Bestehorn, H.P., Neumann, F.J., Büttner, H.J., Betz, P., Stürzenhofecker, P., von Hodenberg, E., Verdun, A., Levai, L., Monassier, J.P., Roskamm, H., 2004. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: the randomized, double-blind, placebo-controlled, multicenter verapamil slow-release for prevention of cardiovascular events after angioplasty (VESPA) Trial. Journal of the American College of Cardiology, 43(12):2160-2165.

[3]Cosgrave, J., Melzi, G., Corbett, S., Biondi-Zoccai, G.G., Agostoni, P., Babic, R., Airoldi, F., Chieffo, A., Sangiorgi, G.M., Montorfano, M., et al., 2007a. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice. Journal of the American College of Cardiology, 49(24):2320-2328.

[4]Cosgrave, J., Melzi, G., Corbett, S., Biondi-Zoccai, G.G., Babic, R., Airoldi, F., Chieffo, A., Sangiorgi, G.M., Montorfano, M., Michev, I., et al., 2007b. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. American Heart Journal, 153(3):354-359.

[5]Degertekin, M., Regar, E., Tanabe, K., Smits, P.C., van der Giessen, W.J., Carlier, S.G., de Feyter, P., Vos, J., Foley, D.P., Ligthart, J.M., et al., 2003. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. Journal of the American College of Cardiology, 41(2):184-189.

[6]Dussaillant, G.R., Mintz, G.S., Pichard, A.D., Kent, K.M., Satler, L.F., Popma, J.J., Wong, S.C., Leon, M.B., 1995. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. Journal of the American College of Cardiology, 26(3):720-724.

[7]Garg, S., Smith, K., Torguson, R., Okabe, T., Slottow, T.L., Steinberg, D.H., Roy, P., Xue, Z., Gevorkian, N., Satler, L.F., 2007. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. Catheterization and Cardiovascular Interventions, 70(1):9-14.

[8]Hoffmann, R., Mintz, G.S., Dussaillant, G.R., Popma, J.J., Pichard, A.D., Satler, L.F., Kent, K.M., Griffin, J., Leon, M.B., 1996. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation, 94(6):1247-1254.

[9]Holmes, D.R.Jr., Teirstein, P., Satler, L., Sketch, M., O'Malley, J., Popma, J.J., Kuntz, R.E., Fitzgerald, P.J., Wang, H., Caramanica, E., et al., 2006. Sirolimus-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. The Journal of the American Medical Association, 295(11):1264-1273.

[10]Kastrati, A., Mehilli, J., Dirschinger, J., Pache, J., Ulm, K., Schühlen, H., Seyfarth, M., Schmitt, C., Blasini, R., Neumann, F.J., et al., 2001. Restenosis after coronary placement of various stent types. The American Journal of Cardiology, 87(1):34-39.

[11]Kastrati, A., Mehilli, J., von Beckerath, N., Dibra, A., Hausleiter, J., Pache, J., Schühlen, H., Schmitt, C., Dirschinger, J., Schömig, A., et al., 2005a. Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrence in patient with coronary in-stent restenosis: a randomized controlled trial (ISAR-DESIRE). The Journal of the American Medical Association, 293(2):165-171.

[12]Kastrati, A., Dibra, A., Eberle, S., Mehilli, J., Suárez de Lezo, J., Goy, J.J., Ulm, K., Schömig, A., 2005b. Sirolimus-eluting stents vs. paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. The Journal of the American Medical Association, 294(7):819-825.

[13]Kornowski, R., Hong, M.K., Tio, F.O., Bramwell, O., Wu, H., Leon, M.B., 1998. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. Journal of the American College of Cardiology, 31(1):224-230.

[14]Liistro, F., Fineschi, M., Angioli, P., Sinicropi, G., Falsini, G., Gori, T., Ducci, K., Bravi, A., Bolognese, L., 2006. Effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis: the TRUE (Tuscany registry of sirolimus for unselected in-stent restenosis) Registry. Journal of the American College of Cardiology, 48(2):270-275.

[15]Mehran, R., Dangas, G., Abizaid, A.S., Mintz, G.S., Lansky, A.J., Satler, L.F., Pichard, A.D., Kent, K.M., Stone, G.W., Leon, M.B., 1999. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation, 100(18):1872-1878.

[16]Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., O'Shaughnessy, C., Caputo, R.P., Kereiakes, D.J., Williams, D.O., Teirstein, P.S., et al., 2003. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. The New England Journal of Medicine, 349(14):1315-1323.

[17]Neumann, F.J., Desmet, W., Grube, E., Brachmann, J., Presbitero, P., Rubartelli, P., Mügge, A., Di Pede, F., Füllgraf, D., Aengevaeren, W., et al., 2005. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation, 111(16):2107-2111.

[18]Saia, F., Lemos, P.A., Arampatzis, C.A., Hoye, A., Degertekin, M., Tanabe, K., Sianos, G., Smits, P.C., van der Giessen, W.J., de Feyter, P.J., et al., 2004. Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) registry. Heart, 90(10):1183-1188.

[19]Sardella, G., Colantonio, R., de Luca, L., Conti, G., di Roma, A., Mancone, M., Canali, E., Benedetti, G., Fedele, F., 2009. Comparison between balloon angioplasty and additional coronary stent implantation for the treatment of drug-eluting stent restenosis: 18-month clinical outcomes. Journal of Cardiovascular Medicine (Hagerstown, Md.), 10(6):469-473.

[20]Sousa, J.E., Costa, M.A., Abizaid, A.C., Rensing, B.J., Abizaid, A.S., Tanajura, L.F., Kozuma, K., van Langenhove, G., Sousa, A.G., Falotico, R., et al., 2001. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation, 104(17):2007-2011.

[21]Sousa, J.E., Costa, M.A., Abizaid, A., Sousa, A.G., Feres, F., Mattos, L.A., Centemero, M., Maldonado, G., Abizaid, A.S., Pinto, I., et al., 2003. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation, 107(1):24-27.

[22]Steinberg, D.H., Gaglia, M.A.Jr., Pinto Slottow, T.L., Roy, P., Bonello, L., de Labriolle, A., Lemesle, G., Torguson, R., Kineshige, K., Xue, Z., et al., 2009. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. The American Journal of Cardiology, 103(4):491-495.

[23]Stone, G.W., Ellis, S.G., O'Shaughnessy, C.D., Martin, S.L., Satler, L., McGarry, T., Turco, M.A., Kereiakes, D.J., Kelley, L., Popma, J.J., et al., 2006. Paclitaxel-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. The Journal of the American Medical Association, 295(11):1253-1263.

[24]van der Giessen, W.J., Lincoff, A.M., Schwartz, R.S., van Beusekom, H.M., Serruys, P.W., Holmes, D.R.Jr., Ellis, S.G., Topol, E.J., 1996. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation, 94(7):1690-1697.

[25]Whan Lee, C., Kim, S.H., Suh, J., Park, D.W., Lee, S.H., Kim, Y.H., Hong, M.K., Kim, J.J., Park, S.W., Park, S.J., 2008. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents. Catheterization and Cardiovascular Interventions, 71(5):594-598.